Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 29, 2025
Principal Office: Rockville, Maryland
Context: The filing reports the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the design of a Phase 3 clinical trial for the company's lead candidate, VCN-01.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Developments
- Regulatory Milestone: Received Scientific Advice from the EMA/CHMP on December 29, 2025, concerning the Phase 3 trial design for VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) for metastatic pancreatic adenocarcinoma (PDAC).
- Pathway to Approval: CHMP advised that a future Marketing Authorization Application (MAA) could be supported by a single, high-quality, double-blinded, randomized, placebo-controlled Phase 3 trial demonstrating a compelling benefit-risk ratio.
- Agreed Trial Parameters: The CHMP agreed on inclusion/exclusion criteria, primary endpoint (overall survival), secondary endpoints (progression-free survival, duration of response, patient-reported outcomes), sample size, and the use of an adaptive design.
- Dosing Strategy: CHMP recognized the survival benefits observed in the prior VIRAGE Phase 2b study with two doses of VCN-01. The agency agreed to a dosing regimen using repeated "macrocycles," allowing for more than two doses in the Phase 3 trial, and suggested considering more frequent dosing.
Outlook, Risks, and Management Commentary
Outlook: Management views the CHMP advice as validation of the proposed clinical development strategy, potentially streamlining the path to a future MAA in the EU for first-line treatment of metastatic PDAC.
Risks and Contingencies:
- The filing includes "safe harbor" language indicating that forward-looking statements are subject to risks and uncertainties.
- Success of the Phase 3 trial is contingent on demonstrating a compelling benefit-risk ratio.
- Regulatory approval is not guaranteed even if the trial meets its endpoints.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the specific details of the "adaptive design" agreed upon by the CHMP and its potential impact on trial duration and cost.
- Review the full text of the press release (Exhibit 99.1) for specific timelines regarding the initiation of the Phase 3 trial.
- Confirm the company's current cash runway and capital requirements to fund the proposed Phase 3 trial, as this filing does not disclose financial status.
- Monitor subsequent filings for any updates on the final protocol submission to the EMA or initiation of patient enrollment.